Skip to content

    Asahi Songwon Colors Limited

    ASAHISONG
    Chemicals·12 May 2025
    Management Summary

    Asahi Songwon delivered a strong FY25 performance, marked by significant revenue and EBITDA growth, a return to PAT positivity, and substantial debt reduction. The company benefited from improved operating cash flows and working capital efficiency. While facing challenges from API price crashes and tepid pigment demand, strategic initiatives in AZO and API segments, including capacity expansion and new product launches, are expected to drive future growth and margin expansion.

    Highlights

    7
    • FY25 Revenue increased by 32% to 566 crores (from 429 crores in FY24).

    • FY25 EBITDA grew by 185% to 60 crores (from 21 crores in FY24).

    • FY25 EBITDA margins doubled from 5% to 10%.

    • FY25 PAT turned positive at 17 crores (from negative in FY24).

    • Operating cash flow improved to 57 crores positive (from 9 crores positive in FY24).

    • Total debt reduced from 200 crores (March 2024) to 160 crores (March 2025).

    • Working capital days reduced from ~130 days to ~102 days.

    Concerns

    3
    • API product prices, particularly Pregabalin, have crashed, with a ~15% decrease in prices for most products.

    • General demand scenario in the pigment business is 'not very robust' and 'tepid'.

    • The industry is currently experiencing 'turbulent times with uncertainties and lots of volatility'.

    What Changed1

    vs Q2 FY26

    Guidance items17 → 15 (-2)

    Key financials

    Single quarter

    06 metrics
    1. 01Revenue₹566 Cr+32%YoY
    2. 02EBITDA₹60 Cr+1.9%YoY
    3. 03EBITDA Margin10%
    4. 04PAT₹17 Cr
    5. 05Operating Cash Flow₹57 Cr+5.3%YoY

    Segment breakdown

    AZO Pigment Business
    64% Capacity Utilization (FY24)80% Capacity Utilization (Target FY26)₹70 Cr Top Line (FY24)₹90 Cr Top Line (Target FY26)8% EBITDA (Target FY26)20% Export Mix (Target FY26)
    API Business
    ₹10.5 Cr EBITDA (FY25)₹5 Cr EBITDA (FY24)25% Volume Growth (FY25)10% EBITDA Margin (QoQ)
    Blue Business
    85% Capacity Utilization
    List

    Capital allocation

    3
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Gross ₹160 crores · 2.5x EBITDA

    Liquidity

    Liquidity disclosed

    Operating cash flows from operations were 9 crores positive in 2024 have come out to 57 crores positive in 2025, due to improvement in payables, receivables and inventory levels.

    Guidance & targets

    15
    CategoryTargetPriority
    Revenue
    Top Line Growth
    15%
    High
    Profitability
    EBITDA Growth
    25%
    High
    Profitability
    PBT Growth
    65%
    High
    Profitability
    Consolidated Percentage EBITDA
    12%
    Medium
    AZO Business
    Export Mix
    20-25%
    High
    AZO Business
    Top Client Growth
    25% (from 70 crores to 90 crores)
    High
    AZO Business
    Capacity Utilization
    80-85%
    High
    AZO Business
    Top Line Growth
    26-27%
    High
    AZO Business
    EBITDA
    8-10%
    High
    AZO Business
    Large Orders from Customers
    1-2 customers
    High
    API Business
    EBITDA Margins
    10-11%
    High
    API Business
    Top Line Improvement
    25%
    High
    Overall
    EBITDA Improvement
    25%
    High
    ROCE
    Return on Capital Employed
    15%
    Medium
    Capacity
    Maximum Top Line from Current Capacity
    750 crores
    Medium

    What to watch in Q1 FY26

    5

    Yellow Pigment Line Operationalization

    Within 3-4 months (Q1/Q2 FY26)
    CurrentChinese equipment on its way, 3-4 months to be fully operational
    TargetFully operational, adding ~40 tons capacity

    Why it matters

    Will contribute to capacity and volume growth in the yellow pigment segment, impacting overall AZO performance.

    The Chinese equipment is already on its way and it should be fully operational within about three to four months. So, they should add about 40 tons to our existing capacity of yellow...

    Risks & concerns

    5
    RiskSeverity

    Global Volatility and Uncertainties

    The company is operating in 'turbulent times with uncertainties and lots of volatility' but sees opportunities.Management acknowledged

    medium

    API Product Price Crash

    Prices for key API products, especially Pregabalin, have crashed by ~15%, impacting profitability.Management acknowledged

    high

    Tepid Demand in Pigment Business

    General demand scenario in the pigment business is 'not very robust' and 'tepid'.Management acknowledged

    medium

    Competition in Blue Business

    The blue business environment is challenging with strong competition and not robust demand.Management acknowledged

    medium

    Pregabalin Narcotic Drug Classification Impact

    Analyst inquired about the impact of Pregabalin being categorized as a narcotic drug; management stated no impact as they sell to regulated customers.Analyst downplayed

    low

    Q&A highlights

    8

    “The Chinese equipment is already on its way and it should be fully operational within about three to four months. So, they should add about 40 tons to our existing capacity of yellow... The Capex is about 5 crores.”

    Provides specific timelines and scale of capacity addition for a key product, confirming the investment made.

    asked by Yashvi

    2 min read6 chapters

    Detailed Narrative

    01

    Strong Financial Turnaround in FY25

    Asahi Songwon reported a robust financial performance for FY25, with revenues increasing by 32% to 566 crores from 429 crores in FY24. This growth was accompanied by a significant 185% surge in EBITDA to 60 crores, leading to a doubling of EBITDA margins from 5% to 10%. The company successfully transitioned from a negative PAT in FY24 to a positive PAT of 17 crores in FY25, indicating a strong turnaround in profitability.

    02

    Improved Cash Flow and Debt Reduction

    The company demonstrated strong cash flow generation, with operating cash flow improving substantially from 9 crores in FY24 to 57 crores in FY25. This was attributed to better management of payables, receivables, and inventory levels. Concurrently, Asahi Songwon focused on deleveraging, reducing its total debt from 200 crores in March 2024 to 160 crores in March 2025. The debt-to-equity ratio improved from 0.75 to 0.55, and EBITDA-to-debt dropped to 2.5 times.

    03

    AZO Business: Capitalizing on Tariff Opportunities

    The AZO pigment business is set to benefit from anti-dumping duties of 20-30% imposed on Chinese imports, particularly in the US market. Management anticipates commercial opportunities to reflect in performance by the next quarter, with expectations of securing large quantity orders from 1-2 customers by year-end. A new yellow pigment line, involving a capex of approximately 5 crores, is expected to be fully operational within 3-4 months, adding 40 tons to the existing capacity.

    04

    API Segment: Diversification Amidst Price Pressure

    Despite a challenging environment marked by a ~15% price crash for key API products like Pregabalin, the API segment achieved a 25% increase in volumes. The company is strategically moving towards becoming a multi-product API company, planning to launch new molecules and pursue backward integration for some over the next two years. This strategy aims to enhance profitability and reduce dependency on single products, with a target of 10-11% EBITDA margins for the full year.

    05

    Positive Outlook and Growth Targets for FY26

    Asahi Songwon provided optimistic guidance for the next financial year (FY26), projecting a 15% top-line growth, 25% EBITDA growth, and 65% PBT growth. The company expects AZO capacity utilization to reach 80-85%, driving a 26-27% top-line growth (from 70 crores to 90 crores) and 8-10% EBITDA for the segment. Overall, consolidated EBITDA margins are targeted at around 12% in the coming years, with a long-term ROCE target of 15%.

    06

    Blue Business Stability and Efficiency Focus

    The core blue pigment business continues to operate at a high capacity utilization of 85-87%. While the demand environment for pigments remains tepid, management is confident in sustaining gross margins through ongoing engineering and efficiency improvements. This segment is expected to provide stable performance, although significant growth is not anticipated due to the challenging industry landscape.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.